Sienna Biopharmaceuticals (NASDAQ:SNNA) Shares Down 12.4%
Sienna Biopharmaceuticals Inc (NASDAQ:SNNA)’s stock price fell 12.4% on Tuesday . The stock traded as low as $0.22 and last traded at $0.19, 2,808,198 shares traded hands during trading. A decline of 76% from the average session volume of 11,710,424 shares. The stock had previously closed at $0.22.
Several brokerages have weighed in on SNNA. BMO Capital Markets dropped their price objective on Sienna Biopharmaceuticals to $3.00 and set an “outperform” rating on the stock in a research note on Thursday, September 5th. ValuEngine upgraded Sienna Biopharmaceuticals from a “hold” rating to a “buy” rating in a research note on Tuesday, October 1st. Two research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. Sienna Biopharmaceuticals presently has an average rating of “Buy” and an average target price of $17.00.
The company has a market capitalization of $5.99 million, a P/E ratio of -0.05 and a beta of 2.67. The company has a debt-to-equity ratio of 1.11, a quick ratio of 2.43 and a current ratio of 2.43. The stock has a 50 day moving average price of $0.42 and a 200 day moving average price of $1.08.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Canada Pension Plan Investment Board bought a new stake in shares of Sienna Biopharmaceuticals during the 2nd quarter worth $26,000. A.R.T. Advisors LLC raised its stake in shares of Sienna Biopharmaceuticals by 84.5% during the 2nd quarter. A.R.T. Advisors LLC now owns 32,653 shares of the company’s stock worth $28,000 after purchasing an additional 14,954 shares during the period. Citadel Advisors LLC raised its stake in shares of Sienna Biopharmaceuticals by 152.3% during the 2nd quarter. Citadel Advisors LLC now owns 40,555 shares of the company’s stock worth $35,000 after purchasing an additional 24,480 shares during the period. Jane Street Group LLC bought a new stake in shares of Sienna Biopharmaceuticals during the 2nd quarter worth $50,000. Finally, Paloma Partners Management Co bought a new stake in shares of Sienna Biopharmaceuticals during the 2nd quarter worth $60,000. Institutional investors own 45.87% of the company’s stock.
About Sienna Biopharmaceuticals (NASDAQ:SNNA)
Sienna Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of drugs in various therapeutic areas. It develops therapies in immunology and inflammation that target select pathways in tissues, such as skin. The company's lead product candidates include SNA-120, a first-in-class inhibitor of tropomyosin receptor kinase A, which is in a Phase IIb clinical trial for the treatment of psoriasis and associated pruritus; and SNA-125, a topical dual Janus kinase 3 inhibitor that is in Phase I/II clinical trials for the treatment of atopic dermatitis, psoriasis, and pruritus.
Featured Article: What is the price-sales ratio?
Receive News & Ratings for Sienna Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sienna Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.